Patents Assigned to Oregon Health Sciences University
  • Patent number: 10899733
    Abstract: Provided herein are compounds of Formula I, or a pharmaceutically acceptable salt thereof: which are useful as PARP inhibitors, as well as pharmaceutical compositions comprising them and methods for their use in treating disorders.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: January 26, 2021
    Assignee: Oregon Health & Science University
    Inventors: Michael Cohen, Rory Morgan
  • Patent number: 10894078
    Abstract: Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach. Also provided are HIV-1 vaccines comprising a carrier, a population episensus antigen, and a tailored antigen. Also provided are methods of designing and producing an HIV-1 vaccine for a subject comprising designing vaccine antigens to optimally cover the diversity within a geographic area using an antigen amino acid sequence generated using the EpiGraph approach, and producing said designed vaccine antigen. Also provided are methods of inducing an effector memory T cell response comprising designing the one or more EpiGraph amino acid sequences, producing a vaccine comprising the one or more EpiGraph amino acid sequences and a vector, and administering the vaccine to a subject. Further provided are methods of treating HIV-1 in a subject comprising administering an effective amount of the described HIV-1 vaccines to the subject in need thereof.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: January 19, 2021
    Assignees: Vir Biotechnology, Inc., Triad National Security, LLC, Oregon Health & Science University
    Inventors: Eric Bruening, Klaus Frueh, Louis Picker, Bette T. M. Korber, James Theiler, Emily Marshall
  • Publication number: 20210002208
    Abstract: Compounds are provided that function as thyromimetics, which compounds have utility for treating diseases such as neurodegenerative disorders. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation. Such compounds have the structure of Formula (I) as shown herein, or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof.
    Type: Application
    Filed: February 13, 2019
    Publication date: January 7, 2021
    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventor: Thomas SCANLAN
  • Publication number: 20200405669
    Abstract: Methods of treating a subject having or at risk of developing a neurodegenerative disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath are described. The methods include administration of a therapeutically effective amount of sobetirome, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 7, 2020
    Publication date: December 31, 2020
    Applicants: Oregon Health & Science University, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Thomas S. Scanlan, Meredith Hartley, Andrew Placzek, Marco Righi, Dennis Bourdette, Gail Marracci, Priya Chaudhary
  • Patent number: 10870616
    Abstract: Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: December 22, 2020
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Thomas Scanlan, Jordan Devereaux, Andrew Placzek, Tapasree Banerji, Skylar Ferrara, James Matthew Meinig, Tania Banerji
  • Patent number: 10857174
    Abstract: Disclosed are morpholino oligonucleotides that can be used to silence expression of MGMT, pharmaceutical compositions that include said morpholino oligonucleotides, and methods of using said morpholino oligonucleotides in the treatment of cancer, particularly methods that involve the use of radiation to deliver said morpholino oligonucleotides.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: December 8, 2020
    Assignees: UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Prakash Ambady, Jeffrey Wu, Edward Neuwelt
  • Patent number: 10845071
    Abstract: A building may include a floor, a dome having a vent, and an internal ceiling that divides areas underneath the dome into first and second chambers. The internal ceiling may have an aperture that is structured to allow air to pass from the first chamber into the second chamber. The building may also include an air inlet configured to allow air to travel from outside the building into the first chamber and an air moving device that is configured to facilitate the movement of the air. The building may also include an air cooling element that is configured to cool the air as it travels from outside the building into the first chamber.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: November 24, 2020
    Assignee: Oregon Health & Science University
    Inventor: Perry Gliessman
  • Patent number: 10835159
    Abstract: A method or system for imaging and quantifying placental blood perfusion using magnetic resonance image. The method or system provides a noninvasive means of assessing placental function and oxygenation from T2* images without the administration of an exogenous contrast agent. The method or system provides quantitative information regarding the number and spatial distribution of perfusion domains which subdivide the placenta into functional units where oxygen transport occurs, along with estimates of fetal oxyhemoglobin concentration, descriptors of placental oxygen reserve, and parameters representing the facility with which oxygen transport from the maternal to fetal vasculature occurs.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: November 17, 2020
    Assignee: Oregon Health & Science University
    Inventors: Matthias Schabel, Antonio Frias, Christopher Kroenke
  • Publication number: 20200342595
    Abstract: An example method includes generating, using a multi-scale block of a convolutional neural network (CNN), a first output image based on an optical coherence tomography (OCT) reflectance image of a retina and an OCT angiography (OCTA) image of the retina. The method further includes generating, using an encoder of the CNN, at least one second output image based on the first output image and generating, using a decoder of the CNN, a third output image based on the at least one second output image. An avascular map is generated based on the third output image. The avascular map indicates at least one avascular area of the retina depicted in the OCTA image.
    Type: Application
    Filed: April 24, 2020
    Publication date: October 29, 2020
    Applicant: Oregon Health & Science University
    Inventors: Yali Jia, Yukun Guo
  • Publication number: 20200325092
    Abstract: Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.
    Type: Application
    Filed: December 9, 2019
    Publication date: October 15, 2020
    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Thomas SCANLAN, Jordan DEVEREAUX, Andrew PLACZEK, Tapasree BANERJI, Skylar FERRARA, James Matthew MEINIG, Tania BANERJI
  • Patent number: 10786541
    Abstract: A method of treating heart disease and/or injury in a subject includes administering to the subject a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of PTP?.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: September 29, 2020
    Assignees: CASE WESTERN RESERVE UNIVERSITY, OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Bradley T. Lang, Jerry Silver, Ryan Gardner, Beth Habecker
  • Publication number: 20200288971
    Abstract: Disclosed herein are methods for simulating the results of a visual field (VF) test using an optical coherence tomography (OCT) system. The disclosed methods may utilize structural information extracted from OCT image datasets, such as thickness measurements, or may utilize functional information, such as blood perfusion measurements, extracted from OCT angiography (OCTA) image datasets.
    Type: Application
    Filed: March 16, 2020
    Publication date: September 17, 2020
    Applicant: Oregon Health & Science University
    Inventors: David Huang, Ou Tan, Liang Liu
  • Publication number: 20200283745
    Abstract: The present disclosure provides polypeptides that have the ability to repair DNA damage by recognizing and removing a wide variety of DNA damage and distortions in double-stranded DNA. In particular, the polypeptides have the ability to remove cyclobutane pyrimidine dimers (CPDs) and/or (6-4) photoproducts from DNA. The polypeptides include at least one heterologous targeting sequence.
    Type: Application
    Filed: November 14, 2018
    Publication date: September 10, 2020
    Applicant: Oregon Health & Science University
    Inventors: R. Stephen Lloyd, Amanda K. McCullough
  • Publication number: 20200276050
    Abstract: Disclosed are implantable ocular drainage devices that include a reversible switch mechanism to control flow through the drainage device. The devices include a drainage tube and a reversible, bi-stable switch mechanism that includes first and second stationary magnets spaced apart from one another and a magnetic or ferromagnetic mobile element moveably disposed in a channel in the housing.
    Type: Application
    Filed: September 11, 2018
    Publication date: September 3, 2020
    Applicant: Oregon Health & Science University
    Inventors: David SIMONS, Robert KINAST
  • Patent number: 10760097
    Abstract: Disclosed herein are recombinant CMV vectors which may comprise a heterologous antigen that can repeatedly infect an organism while inducing a CD8+ T cell response to immunodominant epitopes of the heterologous antigen. The CMV vector may comprise a deleterious mutation in the US11 glycoprotein or a homolog thereof.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: September 1, 2020
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Louis Picker, Klaus Früh, Scott G. Hansen
  • Publication number: 20200273218
    Abstract: Disclosed herein are methods and systems for automated detection of shadow artifacts in optical coherence tomography (OCT) and/or OCT angiography (OCTA). The shadow detection includes applying a machine-learning algorithm to the OCT dataset and the OCTA dataset to detect one or more shadow artifacts in the sample. The machine-learning algorithm is trained with first training data from first training samples that include manufactured shadows and no perfusion defects and second training data from second training samples that include perfusion defects and no manufactured shadows. The shadow artifacts in the OCTA dataset and/or OCT dataset may be suppressed to generate a shadow-suppressed OCTA dataset and/or a shadow-suppressed OCT dataset, respectively. Other embodiments may be described and claimed.
    Type: Application
    Filed: February 27, 2020
    Publication date: August 27, 2020
    Applicant: Oregon Health & Science University
    Inventors: Acner Camino, David Huang, Yali Jia
  • Patent number: 10746742
    Abstract: Disclosed herein are methods of high-throughput mapping of viral neutralizing antibody epitopes. Also disclosed are in vitro immunoprecipitation-based adenoassociated virus Barcode-Seq-based methods of mapping viral neutralizing antibody epitopes. In some embodiments, a method of high-throughput mapping of viral NtAb conformational epitopes can be utilized, which may comprise HP scanning of mutant viral libraries, immunoprecipitation (IP), and/or next-generation sequencing (NGS) technology. In some embodiments, a method of identifying one or more dominant epitopes in a viral vector may comprise contacting a mutant capsid of a virus with serum from a subject previously exposed to the virus and immunopredpitating serum immunoglobulins from the serum. In various embodiments, the viral vector may be an AAV vector.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: August 18, 2020
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Hiroyuki Nakai, Kei Adachi
  • Publication number: 20200237898
    Abstract: Provided herein are optimized recombinant influenza HA polypeptides that elicit immune responses. Also provided are compositions and kits comprising the optimized HA polypeptides as well as methods of making and using the optimized HA polypeptides.
    Type: Application
    Filed: September 21, 2016
    Publication date: July 30, 2020
    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Ted Milburn Ross, Terrianne Maiko Wong, Donald Martin Carter, Jr., Corey John Crevar
  • Publication number: 20200219619
    Abstract: An example method includes identifying training data indicating features of a sample population and clinical outcomes of the sample population. The clinical outcomes are associated with a heterogeneous condition. The method further includes generating decision trees in a Random Forest (RF) based on the training data, each one of the decision trees being configured to divide the sample population into multiple categories based on the features of the sample population. In response to generating the decision trees, a proximity matrix comprising multiple entries is generated using the RF. One of the entries indicates a proportion of the decision trees that categorize a first individual among the sample population and a second individual among the sample population into the same categories among the multiple categories. The method further includes identifying subgroups of the heterogeneous condition by detecting communities of the proximity matrix.
    Type: Application
    Filed: December 19, 2019
    Publication date: July 9, 2020
    Applicant: Oregon Health & Science University
    Inventors: Eric Feczko, Damien A. Fair, Shannon McWeeney
  • Patent number: 10702303
    Abstract: Retreating stop ultrasound needle guide systems are disclosed. In one example approach, a needle guide system includes a guiding component which can be positioned at different locations and angles on a mounting component, where the mounting component can be coupled to a distal end of an ultrasound probe. When positioned at the different locations and angles on the mounting component, the guiding component can guide a needle through the skin of a patient at a constant point and when the needle is advanced so that a hub of the needle reaches a stop of the guiding component, a tip of the needle is positioned directly underneath the ultrasound at a pre-selected depth.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: July 7, 2020
    Assignee: Oregon Health & Science University
    Inventor: Andrew Neice